Kepler Cheuvreux Suisse SA Makes New Investment in Labcorp Holdings Inc. $LH

Kepler Cheuvreux Suisse SA acquired a new position in shares of Labcorp Holdings Inc. (NYSE:LH) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 13,507 shares of the medical research company’s stock, valued at approximately $3,389,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of LH. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp during the 4th quarter worth about $26,000. JPL Wealth Management LLC acquired a new stake in Labcorp during the 3rd quarter worth about $28,000. Eagle Bay Advisors LLC acquired a new stake in Labcorp during the 4th quarter worth about $29,000. Beacon Financial Strategies CORP acquired a new stake in Labcorp during the 4th quarter worth about $33,000. Finally, Headlands Technologies LLC raised its holdings in Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after buying an additional 96 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Buying and Selling

In other Labcorp news, EVP Brian J. Caveney sold 1,500 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president owned 30,107 shares in the company, valued at $8,619,935.17. This trade represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Adam H. Schechter sold 8,705 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total value of $2,437,051.80. Following the transaction, the chief executive officer owned 80,773 shares in the company, valued at approximately $22,613,209.08. This trade represents a 9.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 16,113 shares of company stock worth $4,547,450. 0.84% of the stock is currently owned by company insiders.

Labcorp Trading Down 0.0%

Shares of LH stock opened at $253.99 on Monday. Labcorp Holdings Inc. has a 12 month low of $239.67 and a 12 month high of $293.72. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The business’s 50 day moving average is $269.03 and its two-hundred day moving average is $266.77. The company has a market cap of $20.83 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 1.78 and a beta of 0.91.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter last year, the company posted $3.84 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities analysts predict that Labcorp Holdings Inc. will post 17.99 EPS for the current year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Piper Sandler boosted their price objective on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. JPMorgan Chase & Co. upped their target price on Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Labcorp presently has an average rating of “Moderate Buy” and an average target price of $308.00.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.